Navigation Links
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
Date:10/3/2008

Companies to Study B-Raf Kinase Inhibitors for Cancer Treatments

INDIANAPOLIS, Ind. and LAWRENCE, Kan., Oct. 3 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and privately-held Deciphera Pharmaceuticals, LLC today announced that the two companies have entered into a collaboration and worldwide licensing agreement related to Deciphera's preclinical B-Raf kinase inhibitor program for the study of potential oncology therapeutics.

The collaboration will apply Deciphera's phylomechanics discovery platform, a unique, proprietary approach to kinase inhibitor design, together with Lilly's expertise in discovery, development and commercialization to pursue first-in-class and best-in-class drug candidates for a variety of cancers.

Under the terms of the agreement, Lilly and Deciphera will collaborate in four different project areas involving selective or multi-kinase targeted B-Raf inhibitors. Lilly will obtain exclusive worldwide rights to any products developed as part of this collaboration. In return, Deciphera will receive an upfront payment and research funding over the next two years from Lilly, and may also receive up to $130 million in potential development, regulatory and sales milestones for each of the four project areas. If a product is successfully commercialized from this collaboration, Deciphera will be entitled to royalties on sales.

"This collaboration is further evidence of Lilly's ongoing commitment to oncology research," said Dr. William W. Chin, M.D., vice president of discovery research and clinical investigation for Lilly. "We look forward to working with Deciphera to leverage their B-Raf kinase inhibitor program, with the ultimate goal of developing promising drug candidates for cancer patients."

"The collaboration and license agreement with Lilly marks an important milestone in the growth and development of our company," said Daniel Flynn, President & CEO of Deciphera. "Lilly's strength in drug discovery and development, and in particular their commitment to cancer drug research, provides Deciphera with the opportunity to advance our B-Raf kinase 'switch pocket' inhibitors into the clinic and ultimately to patients in need of these therapies. We are very pleased to have Lilly as our partner in this endeavor."

About B-Raf Inhibitors

BRAF kinase is one of the most frequently mutated members of the kinase family across all cancers, and is particularly common in malignant melanomas, colon, and thyroid cancers. The V600E mutant form of BRAF kinase in particular has been associated with increased tumor aggressiveness and decreased survival rates in many types of cancers. Deciphera is pursuing two distinct strategies centered on BRAF inhibition. The first strategy seeks potent and highly selective BRAF inhibitors. The second strategy pursues BRAF inhibitors which also inhibit other kinases of interest.

About Deciphera

Deciphera Pharmaceuticals, LLC was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce "best-in-class" small molecule switch inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform, Phylomechanics. Deciphera's kinase inhibitors target the mechanisms that render kinases oncogenic, retain potency against gatekeeper mutations, and afford selectivity profiles not easily attained by other approaches. For more information, visit the Company's website at http://www.deciphera.com.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

C-LLY

This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, the completion of clinical trials, the FDA and other foreign review processes and other governmental regulation, Lilly's and Deciphera's abilities to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, the ability to effectively market products, and other factors described in Lilly's most recent filings with the Securities and Exchange Commission. Lilly undertakes no duty to update forward looking statements.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Lilly and TransPharma Medical Announce Licensing and Development Agreement
6. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
7. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
8. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
9. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
10. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
11. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
Breaking Medicine News(10 mins):